Inovio stockholders elect eight directors, approve omnibus plan at annual meeting

On May 19, 2026, the board of directors (the “ Board ”) of Inovio Pharmaceuticals, Inc. (the “ Company ”) approved an amendment to the Company’s Amended and Restated bylaws (the “ Bylaws Amendment ”) effective immediately to further enhance the Company’s corporate governance practices by, among other things, (i) clarifying the role of the Chairman of the Board, including that the Chairman shall not be deemed an officer of the corporation unless expressly designated as such by the Board, (ii) establishing the position of Lead Independent Director, including the designation, duties and responsibilities thereof, and requiring the appointment of a Lead Independent Director in the event the Chief Executive Officer also serves as Chairman of the Board and (iii) updating the order of presiding officers at meetings of the Board and stockholders to reflect the foregoing changes.

Proposal 1 : The election of the following eight nominees as directors of the Company to serve until the Company’s 2027 Annual Meeting of Stockholders and until their successors are elected. The votes were cast as follows: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Simon X. Benito 22,312,198 1,267,180 17,091,251 Roger D. Dansey, M.D. 22,480,244 1,099,134 17,091,251 Ann C. Miller, M.D. 22,544,652 1,034,726 17,091,251 Jacqueline E. Shea, Ph.D. 22,560,816 1,018,562 17,091,251 Jay P. Shepard 22,468,210 1,111,168 17,091,251 David B. Weiner, Ph.D. 22,666,881 912,497 17,091,251 Wendy L. Yarno 22,451,874 1,127,504 17,091,251 Lota S. Zoth 22,455,943 1,123,435 17,091,251

Proposal 4 : The approval of the amendment and restatement of the Company’s Amended and Restated 2023 Omnibus Incentive Plan as described in the Proxy Statement. The votes were cast as follows: For Against Abstain Broker Non-Votes 21,559,350 1,535,940 484,088 17,091,251

Proposal 2 : The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: For Against Abstain Broker Non-Votes 39,329,582 1,198,040 143,007 —

Proposal 3 : The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement. The votes were cast as follows: For Against Abstain Broker Non-Votes 21,500,999 1,607,592 470,787 17,091,251